Pharmaceutical giant Procter & Gamble has been praised for taking a rare stand for honesty in drug marketing by suing its rivals, Roche and GlaxoSmithKline, over allegedly misleading claims that they have made about the effectiveness of their osteoporosis drug Boniva. This is the same P&G, of course, that has been facing international criticism since The Times Higher reported that the company released research findings on its own osteoporosis drug, Actonel, in the name of academic researchers whose access to the drug's raw trial data had been seriously restricted.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login